Kygevvi is a fixed-dose combination medication used for the treatment of a specific rare disease, primarily indicated for patients with TK2 deficiency.

I. Indications of Kygevvi

The indications for Kygevvi (doxercalcitol and doxorubicin) are clearly and strictly defined. It is approved for the treatment of TK2 deficiency, a rare disorder caused by gene mutations that lead to mitochondrial DNA depletion, resulting in progressive muscle weakness and various severe complications.

Patient Population

(1) This drug is applicable to both adult and pediatric patients.

(2) A key restriction is that the onset age of symptoms for TK2 deficiency must be 12 years or younger. The drug is not approved for patients with symptom onset after the age of 12.

Core Mechanism of Action

By supplementing specific pyrimidine nucleosides (deoxycytidine and deoxythymidine), the drug aims to restore the copy number of mitochondrial DNA in patients' skeletal muscle cells, thereby treating the fundamental pathophysiological process of the disease.

II. Contraindications and Food Restrictions of Kygevvi

Contraindications

Currently, Kygevvi has no absolute drug contraindications. This means that for diagnosed patients meeting the indication criteria, no specific health condition completely prohibits its use.

Food Restrictions and Administration Requirements

(1) Do not take on an empty stomach: Kygevvi must be taken with food. Clinical data shows that taking with meals significantly increases the absorption of both active ingredients compared to fasting. Taking it on an empty stomach without authorization may lead to insufficient efficacy.

(2) Dedicated Solvent: When preparing the oral solution, the powder must be mixed with room-temperature water only. It is strictly prohibited to use juice, milk, carbonated beverages, or any other liquid as a substitute for water during preparation or administration.

(3) Dedicated Equipment: Preparation and administration must use the dedicated ZX2000 administration kit (mixing bottle, administration cup, oral syringe) provided with the drug. The use of non-dedicated tools such as household measuring spoons or cups is forbidden to ensure accurate dosing.

(4) Avoid Substances with Unknown Ingredients: During treatment, avoid simultaneous ingestion of health supplements or herbal medicines with complex ingredients that may affect the gastrointestinal tract, liver, or kidney functions, unless evaluated by a doctor.

III. Key Administration Points for Special Populations

Pediatric Use

(1) The safety and efficacy of Kygevvi have been confirmed in pediatric patients meeting the indication (symptom onset age ≤ 12 years).

(2) However, in clinical trials, the incidence of vomiting and increased liver enzymes in pediatric patients was higher than in adults, requiring closer monitoring by parents and physicians.

(3) Cases of severe diarrhea leading to hospitalization have also been reported in children. In case of persistent diarrhea or vomiting, medical attention must be sought immediately.

Pregnancy and Lactating Women

(1) Pregnancy: There is a lack of safety data for human use during pregnancy. Animal studies have shown teratogenic risks in rabbits at extremely high doses. Therefore, the pregnancy status or plans must be disclosed to the doctor before use. The doctor must carefully balance the therapeutic benefit for the mother against the potential risks to the fetus before deciding whether to prescribe the drug.

(2) Lactation: It is unknown whether the drug enters human milk or has an impact on breastfeeding infants. It is recommended that lactating women discuss the best feeding plan with their doctors during treatment.

Patients with Hepatic or Renal Insufficiency

(1) Hepatic Insufficiency: The drug itself may cause increased liver enzymes, and liver injury is one of the manifestations of TK2 deficiency itself. Liver function (ALT, AST, total bilirubin) must be monitored regularly before and during treatment. If signs of liver injury occur, treatment must be interrupted immediately.

(2) Renal Insufficiency: Moderate and severe renal impairment significantly increases the blood concentration of both drug ingredients. Since the dosage of both ingredients cannot be adjusted individually, the use of Kygevvi in such patients requires extreme caution. There is no clear dosage adjustment guideline for patients with renal insufficiency, and doctors must assess the risks and benefits based on individual circumstances.

Geriatric Use

(1) Existing clinical studies have not included a sufficient number of patients aged 65 years and older, so it cannot be determined whether the response in geriatric patients differs from that in young adults.

(2) Its use in geriatric patients should be judged cautiously based on individual circumstances.